知識資本主義における貧困化の構図

• 斎藤 厚

  日本赤十字社長崎原爆諌早病院

• 谷川原 祐介

  慶應義塾大学医学部薬剤部

• 渡辺 彰

  東北大学加齢医学研究所抗感染症薬開発研究部門

• 青木 信樹

  新潟市社会事業協会信楽園病院内科

• 二木 芳人

  昭和大学医学部臨床感染症学講座

• 河野 茂

  長崎大学大学院医歯薬学総合研究科感染免疫学講座 (第二内科)

• 賀来 満夫

  東北大学大学院医学系研究科内科病態学講座感染制御・検査診断学分野

• 堀 誠治

  東京慈恵会医科大学薬理学講座

• 戸塚 恭一

  東京女子医科大学感染対策部感染症科

書誌事項

タイトル別名

• Open study of sitafloxacin in patients with respiratory tract infections
• 呼吸器感染症に対するsitafloxacinの一般臨床試験
• チシキ シホン シュギ ニ オケル ヒンコンカ ノ コウズ
• PK/PD study

抄録

Sitafloxacin (STFX), a fluoroquinolone antimicrobial agent, has a broad spectrum ofactivity and a potent antimicrobial activity against Streptococcus pneumoniae which is a major pathogen in respiratory tract infections (RTI). This clinical study was conducted to confirm the clinical recommended dose of STFX as 50mg b.i.d. for RTI from PK/PD.<BR>Clinical efficacy was 92.3%(96/104) in the 50mg b.i.d. group and 93.1%(27/29) in the 100 mg bid. group. Bacteriological efficacy was 89.1%(57/64) in the 50mg b.i.d. group and 82.4%(14/17) in the 100mg bid. group. Eradication of major causative organisms was 91.7%(22/24) in S.pneumoniae and 100%(24/24) in Haemophilus influenzae.<BR>Steady state C_max and AUC_0-24h after repeated oral administration of STFX to patients with RTI were 0.57±0.21μg/mL and 9.38±4.24μg·h/mL in the 50mg b.i.d. group, and 1.17±0.45μg/mL and 17.16±6.52μg·h/mL in the 100 mg b.i.d. group.<BR>If C_max/MIC was 5 or below, or AUC_0-24h/MIC was 100 or below, eradication were 33.3%(3/9) or 40.0%(4/10).In contrast, if Cmax/MIC was over 5, it was 96.3%(79/82). If AUC_0-24h/MIC wasover 100, it was 96.3%(78/81).MIC₉₀ of STFX against the causative organisms in this study was 0.1μg/mL. Results suggest that 50mg b.i.d. of STFX can achieve C_max/MIC 5 and AUC_0-24h/MIC 100 against 90% of the causative organisms in RTI.<BR>Adverse drug reactions (ADR) occurred in 43.5%(50/115 patients) in the 50mg b.i.d. group and 42.4%(14/33 patients) in the 100mg b.i.d. group. The major ADR was diarrhoea (20/148, 13.5%). C_max and AUC_0-24h of patientsin whom diarrhoea or soft stool occurred tended to be higher than in patients free of these symptoms. No severe ADRs were observed in either groups.<BR>Results suggest that a dose of 50mg b.i.d. of STFX is optimal in the treatment of RTI.

収録刊行物

• 日本化学療法学会雑誌

  日本化学療法学会雑誌 56 (Supplement1), 63-80, 2008

  公益社団法人 日本化学療法学会

キーワード

• respiratory tract infection
• PK/PD
• sitafloxacin
• fluoroquinolone

詳細情報

• CRID: 1390282681264794880
• NII論文ID: 110007007450
• NII論文ID: 10021192816
• NII論文ID: 130004102789
• NII書誌ID: AN10407566
• ISSN: 13417843
• ISSN: 18845886
• ISSN: 13407007
• DOI: 10.11250/chemotherapy1995.56.supplement1_63
• NDL書誌ID: 10199452
• Web Site: http://id.nii.ac.jp/1114/00001761/
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I10199452
• Web Site: https://search.jamas.or.jp/link/ui/2008207510
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • IRDB
  • NDL
  • CiNii Articles
  • KAKEN
• 抄録ライセンスフラグ: 使用不可